Can alteplase be administered intra‑arterially?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Alteplase Be Given Intra-Arterially?

Yes, alteplase can be administered intra-arterially for acute ischemic stroke, though this is not the standard first-line approach and is typically reserved for specific clinical scenarios after or in conjunction with mechanical thrombectomy.

Standard of Care: Intravenous Route First

Intravenous alteplase remains the cornerstone and standard of care for acute ischemic stroke treatment 1. The approved dosing is 0.9 mg/kg (maximum 90 mg) with 10% given as a bolus over 1 minute and the remaining 90% infused over 60 minutes 1. This intravenous route should not be delayed or withheld simply because intra-arterial options are available 2.

When Intra-Arterial Alteplase Is Indicated

1. After Mechanical Thrombectomy (Adjunctive Therapy)

The most recent and highest-quality evidence comes from the CHOICE-2 trial (2026), which demonstrated that adjunctive intra-arterial alteplase after successful thrombectomy:

  • Increased excellent functional outcomes (mRS 0-1) from 42.5% to 57.5% (15% absolute benefit, P=0.002) 3
  • Reduced residual hypoperfusion from 50.5% to 28.6% 3
  • Did not significantly increase symptomatic intracranial hemorrhage (1.4% vs 0.5%, P=0.33) 3

However, there was increased mortality (12.1% vs 6.4%, P=0.03) in the intra-arterial alteplase group, which requires careful consideration 3.

The dosing used was 0.225 mg/kg (maximum 20 mg) infused over 15 minutes 3.

2. Middle Cerebral Artery Occlusion Within 6 Hours

Intra-arterial thrombolysis is indicated for selected patients with major stroke of ≤6 hours duration due to middle cerebral artery occlusion (Class I, Level B evidence) 2. This is based on the PROACT-II trial, which showed 15% absolute benefit in achieving mRS ≤2 at 90 days 2.

3. Contraindications to Intravenous Thrombolysis

Intra-arterial thrombolysis is reasonable for patients who have contraindications to IV thrombolysis, such as recent surgery (Class IIa, Level C) 2.

4. Combined IV/IA Approach

The combined intravenous and intra-arterial approach appears safe and has been investigated 4. Patients eligible for both IV alteplase and endovascular thrombectomy should receive IV alteplase first, which can be initiated while simultaneously preparing for thrombectomy 1.

Important Caveats and Pitfalls

Posterior Circulation Strokes

The IAT-TOP trial (2026) showed that in basilar artery occlusion, intra-arterial alteplase after successful thrombectomy was not associated with improved functional outcomes (41.9% vs 46.7% functional independence, P=0.55) 5. This suggests the benefit may be limited to anterior circulation strokes.

Dosing Considerations

  • Intra-arterial doses are much lower than IV doses: typically 5-20 mg total 3, 6, 7
  • Doses up to 69 mg have been studied without dose-related increase in intracranial hemorrhage 7
  • The FDA label for alteplase does not specifically address intra-arterial administration for stroke 8

Facility Requirements

Intra-arterial thrombolysis requires:

  • An experienced stroke center with immediate access to cerebral angiography 2
  • Qualified interventionalists with appropriate credentialing 2
  • 24/7 availability of neurointervention expertise 1

Safety Profile

While intra-arterial alteplase appears relatively safe when used adjunctively:

  • Symptomatic ICH rates remain low (1-2%) 3, 5
  • The mortality signal in CHOICE-2 warrants caution and further investigation 3
  • There may be increased risk of ventricular arrhythmias during administration 9

Clinical Algorithm

For patients with acute ischemic stroke and large vessel occlusion:

  1. Always give IV alteplase first if eligible (within 4.5 hours, no contraindications)
  2. Proceed immediately to mechanical thrombectomy if indicated (don't wait to assess IV alteplase response)
  3. After achieving successful recanalization (eTICI 2b50-3):
    • Consider adjunctive intra-arterial alteplase (0.225 mg/kg, max 20 mg over 15 minutes) for anterior circulation strokes
    • Weigh the potential 15% improvement in excellent outcomes against the mortality signal
    • Do not use routinely for posterior circulation based on IAT-TOP results
  4. For suboptimal recanalization (TICI ≤2b):
    • Consider rescue intra-arterial alteplase (5-15 mg), particularly for distal emboli 6

The decision to use intra-arterial alteplase should involve stroke neurology and neurointerventional consultation, with shared decision-making including discussion of both the functional benefit and mortality risk.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.